Rhabdomyosarcoma of the cervix uteri

Rhabdomyosarcoma of the cervix uteri is an extremely rare malignant tumor arising from skeletal muscle precursor cells (rhabdomyoblasts) within the uterine cervix. It is classified under soft tissue sarcomas and primarily affects the female reproductive system. The most common histological subtype occurring in the cervix is embryonal rhabdomyosarcoma, particularly the botryoid variant (sarcoma botryoides), which characteristically presents as grape-like polypoid masses protruding from the cervical os. This tumor predominantly affects young women, including children, adolescents, and young adults, though rare cases have been reported in older women. Key symptoms include abnormal vaginal bleeding, vaginal discharge, and the presence of a visible or palpable polypoid mass protruding from the vagina. Patients may also experience pelvic pain or pressure symptoms depending on tumor size. In advanced cases, the tumor may spread locally to surrounding pelvic structures or metastasize to distant sites including the lungs, lymph nodes, and bone marrow. Treatment typically involves a multimodal approach combining chemotherapy, surgery, and sometimes radiation therapy. Chemotherapy regimens commonly include vincristine, actinomycin D, and cyclophosphamide (VAC protocol), often administered as neoadjuvant therapy to reduce tumor size before surgical resection. Conservative fertility-sparing surgery may be considered in younger patients with localized disease, while more extensive surgery may be necessary for advanced cases. The prognosis for cervical rhabdomyosarcoma, particularly the botryoid subtype, is generally more favorable than rhabdomyosarcomas at many other sites, especially when diagnosed at an early stage and treated with contemporary multimodal protocols.

Common questions about Rhabdomyosarcoma of the cervix uteri